Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit311.htm |
| EX-23.2 - EXHIBIT 23.2 CONSENT OF BDO - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit232consen.htm |
| EX-23.1 - EXHIBIT 23.1 CONSENT OF KPMG 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit231consen.htm |
| EX-10.15 - EXHIBIT 10.15 JIMHERMAN 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1015jimhe.htm |
| EX-10.14 - EXHIBIT 10.14 MICHAELBONNER 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1014micha.htm |
| EX-10.13 - EXHIBIT 10.13 LEO PAVLIV 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1013leopa.htm |
| EX-10.12 - EXHIBIT 10.12 MARTINCEARNAL 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1012marti.htm |
| EX-10.11 - EXHIBIT 10.11 AJKAZIMI 2018 - CUMBERLAND PHARMACEUTICALS INC | a2017-10kxexhibit1011ajkaz.htm |
| 10-K - 10-K 2017 - CUMBERLAND PHARMACEUTICALS INC | a2017-10k.htm |
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Cumberland Pharmaceuticals Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, A.J. Kazimi, Chief Executive Officer, and Michael P. Bonner, Senior Director and Chief Financial Officer, of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that, based on my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ A.J. Kazimi | |
A.J. Kazimi | |
Chief Executive Officer | |
March 9, 2018 | |
/s/ Michael P. Bonner | |
Michael P. Bonner | |
Senior Director and Chief Financial Officer | |
March 9, 2018 | |